Pixantrone gets orphan-drug status from European regulator

12/21/2009 | Reuters

The European Medicines Agency granted orphan-drug designation to Cell Therapeutics' pixantrone as a treatment for diffuse large B-cell lymphoma. The biotech firm plans to submit the product for European approval next year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA